Three presentations at this week’s 2017 American College of Rheumatology Annual Meeting in San Diego, CA, cover research on pharmacokinetic equivalence, safety, and switching of 2 proposed adalimumab biosimilars, GP2017 and CHS-1420.
Three presentations at this week’s 2017 American College of Rheumatology (ACR) Annual Meeting in San Diego, CA, cover research on pharmacokinetic (PK) equivalence, safety, and switching of 2 proposed adalimumab biosimilars, GP2017 and CHS-1420.
PK, Immunogenicity, and Safety of GP2017
The first study1, by Julia Jauch-Lembach, MD, and colleagues at Hexal AG and PAREXEL International GmbH, compared the PK, immunogenicity, and safety of Hexal’s proposed adalimumab biosimilar GP2017, EU-authorized adalimumab, and US-approved adalimumab in 318 healthy men. The results of their 3-arm parallel trial show that GP2017 is bioequivalent to EU and US adalimumab, and that EU adalimumab is bioequivalent to US adalimumab. In addition, the researchers said, “There were no clinically relevant differences in safety, tolerability, and immunogenicity among the 3 treatment arms in healthy subjects.”
PK equivalence was demonstrated between GP2017 and EU adalimumab and between EU and US adalimumab by describing the maximum observed serum concentration (Cmax) and total area under the curve (AUC0-inf). Secondary objectives included assessment of AUC0-360h and AUC0-last, the comparison of PK parameters between GP2017 and US-adalimumab, and the evaluation of safety, tolerability, and immunogenicity of all 3 products.
The rate of treatment-emergent adverse events (TEAEs) was similar across the GP2017, EU adalimumab, and US adalimumab treatment groups (57.9%, 61.3%, and 58.1%) and all were mild or moderate in severity. Overall, antidrug antibodies (ADAs) were detected in 57.9%, 69.8%, and 69.5% of subjects in the GP2017, EU adalimumab, and US adalimumab groups, respectively, up to day 72.
Long-Term Efficacy Safety and Immunogenicity of GP2017
A second study2 reported the findings of Andrew Blauvelt, MD, MBA, of Hexal AG, and colleagues on the long-term efficacy, safety, and immunogenicity of GP2017 compared with reference adalimumab in 465 patients with moderate to severe plaque psoriasis (including 98 with psoriatic arthritis [PsA]).
Initially, patients were randomized to receive GP2017 (n = 231) or reference adalimumab (n = 234). At Week 17, 379 patients were re-randomized to continue treatment with GP2017 (n = 126) or reference adalimumab (n = 127), or to switch between GP2017 and reference adalimumab or vice versa (n = 63 in each group).
There were no clinically meaningful differences in long-term efficacy among patients who received continued GP2017 and reference adalimumab multiple times. Switching was well tolerated; overall safety profiles and immunogenicity rates were similar among individual treatment groups. “The data add to the totality of evidence suggesting GP2017 could be used as a biosimilar for the treatment of the same indications for which reference adalimumab is approved,” the researchers concluded.
Phase 3 Study on CHS-1420
A third study3 on adalimumab reported the findings of Barbara Finck, MD, and colleagues at Coherus BioSciences in a phase 3, randomized, double-blind, multicenter study evaluating the equivalence of the company’s proposed adalimumab biosimilar CHS-1420 to reference adalimumab in 545 adult patients with moderate-to-severe plaque psoriasis, including patients with PsA. The trial demonstrated the equivalence of CHS-1420 to reference adalimumab based on the primary endpoint (75% reduction in the Psoriasis Area and Severity Index [PASI 75] at week 12). Patients who switched from reference adalimumab to CHS-1420 at week 16 had similar efficacy and safety results at week 24 compared with patients who received only CHS-1420 or reference adalimumab. Results in patients with PsA were similar across treatment groups.
PASI 75 was achieved at week 24 by 84.6%, 81.6%, and 88.3% of patients in the CHS-1420 group, the switched group, and the adalimumab group, respectively, demonstrating maintenance of response, the researchers said. No statistically significant difference was found among treatment groups.
TEAEs were reported in 48.9% and 45% of patients in the CHS-1420 and adalimumab groups, respectively, through week 16, and in 20.1%, 19.4%, and 16.3% of patients in the CHS-1420 group, the switched group, and the adalimumab group, respectively, during weeks 17 to 24.
References
1. Jauch-Lembach J, Skerjanec A, Haliduola H, et al. Randomized, double-blind, single-dose, three-arm parallel trial to determine the pharmacokinetics and safety of GP2017, EU- and US-adalimumab in healthy male subjects. Presented at the American College of Rheumatology 2017 meeting, November 7, 2017; San Diego, California. Abstract 2443. acrabstracts.org/abstract/randomized-double-blind-single-dose-three-arm-parallel-trial-to-determine-the-pharmacokinetics-and-safety-of-gp2017-eu-and-us-adalimumab-in-healthy-male-subjects/.
2. Blauvelt A, Lacour JP, Fowler J, et al. Long-term efficacy, safety and immunogenicity results from a randomized, double-blind, phase III confirmatory efficacy and safety study comparing GP2017, a proposed biosimilar, with reference adalimumab. Presented at the American College of Rheumatology 2017 meeting, November 7, 2017; San Diego, California. Abstract 2440. acrabstracts.org/abstract/long-term-efficacy-safety-and-immunogenicity-results-from-a-randomized-double-blind-phase-iii-confirmatory-efficacy-and-safety-study-comparing-gp2017-a-proposed-biosimilar-with-reference-adalimum/.
3. Hodge J, Tang H, O’Connor P, Finck B. Switching from adalimumab to CHS-1420: A randomized, double-blind global clinical trial in patients with psoriasis and psoriatic arthritis. Presented at the American College of Rheumatology 2017 meeting, November 7, 2017; San Diego, California. Abstract 2879. acrabstracts.org/abstract/switching-from-adalimumab-to-chs-1420-a-randomized-double-blind-global-clinical-trial-in-patients-with-psoriasis-and-psoriatic-arthritis/.
Addressing Patent Abuse, Reimbursement Models Key to Sustainable Biosimilar Market
April 25th 2025Sonia T. Oskouei, PharmD, emphasized strategies to streamline regulations and evolve to overcome barriers and expand the availability of cost-effective biosimilar treatments across more therapeutic areas.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Decade of Biosimilars Yields $36 Billion in Savings and Strengthens Supply Chain
April 24th 2025Dracey Poore, MS, director of biosimilars and emerging therapies at Cardinal Health, highlighted that biosimilars saved $36 billion over the last decade by improving patient access and the supply chain, but continued education and a robust pipeline are crucial for future growth.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Early Success of Adalimumab Biosimilars Featured at AMCP 2025
April 5th 2025High adherence rates, comparable clinical effectiveness, and cost savings have marked the early adoption of adalimumab biosimilars in the US, particularly in formulary-driven transitions, as shown in 2 retrospective studies presented at the Academy of Managed Care Pharmacy annual meeting (AMCP 2025).